Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of triptonide in preparation of medicine for treating acute monocyte leukemia

A kind of technology of triptolide ketone and acute single, applied in the field of leukemia drugs

Pending Publication Date: 2020-07-14
INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about triptolide inhibiting leukemia cell apoptosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of triptonide in preparation of medicine for treating acute monocyte leukemia
  • Application of triptonide in preparation of medicine for treating acute monocyte leukemia
  • Application of triptonide in preparation of medicine for treating acute monocyte leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Detection of cell viability of triptolide against acute monocytic leukemia cell line U937

[0034] experimental method:

[0035] MTT method was used to determine the inhibitory effect of different concentrations of triptolide on the proliferation of U937 leukemia cells.

[0036] Cultivate U937 cells to the logarithmic growth phase. Experiments are carried out when the cells are in good condition. 5000 cells / well are seeded in a 96-well plate, and 100 mmol / L of prepared RPMI1640 medium containing 5% FBS is diluted. Triptolide was diluted to 640nmol / L, 2ml, and diluted to 320nmol / L in a 96-well plate, 160nmol / L, 80nmol / L, 40nmol / L, 20nmol / L, 10nmol / L, 5nmol / L, 2.5 nmol / L, set up 6 replicate wells for each concentration, set up RPMI1640 medium negative control with 5% FBS, fill with sterile PBS for four weeks, and 5% CO 2 , After incubation at 37°C for 48 and 72 hours, add 20 μl of 5% MTT solution to each well, continue to incubate for 4 hours, add 100 μl of 10% SDS cont...

Embodiment 2

[0042] Experimental method for detecting the effect of triptolide on the apoptosis of acute monocytic leukemia cells U937:

[0043] Cultivate U937 cells to the logarithmic growth phase, and carry out the experiment when the cells are in good condition, inoculate 10,000 cells / well in a 6-well plate, dilute the prepared 100mM Tripterygium wilfordii in RPMI1640 medium containing 5% FBS Esterone was diluted to 40nmol / L, 20nmol / L, 10nmol / L, 5nmol / L, 2.5nmol / L, and each concentration was set up 3 duplicate wells, with the RPMI1640 medium of 5%FBS as contrast (control group), in 5%CO 2 After incubation at 37°C for 72 hours, the cells were collected, centrifuged at 200 g to discard the supernatant, washed twice with sterile PBS, added 5 μl of FITCAnnexin to incubate the treated cells for 10 minutes, then added 5 μl of PI, and placed in a room temperature environment for 5 minutes in the dark. Add 100 μl 1×BindingBuffer and mix thoroughly, and detect by flow cytometry within 1 hour. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of triptonide in preparation of a medicine for treating acute monocyte leukemia, and belongs to the technical field of leukemia medicines. According to the application of the triptonide in preparation of the medicine for treating the acute monocyte leukemia, acute monocyte leukemia cells U937 are taken as research objects, U937 cells are treated by a triptonide solution, the cell activity of the U937 cells is detected by an MTT method, and the result shows that the triptonide has an effect of inhibiting proliferation of the U937 leukemia cells. The influenceof the triptonide on apoptosis of the U937 cells is detected by an Annexin V / PI double staining method, and the result shows that the triptonide can induce apoptosis of the U937 cells, and the apoptosis is more obvious along with increase of concentration. Therefore, the triptonide can inhibit proliferation of the acute leukemia cells and induce apoptosis, so that treatment of the acute monocyte leukemia is realized.

Description

technical field [0001] The invention belongs to the technical field of leukemia drugs, and in particular relates to the application of triptolide in the preparation of drugs for treating acute monocytic leukemia. Background technique [0002] Leukemia, also known as blood cancer, is a malignant proliferative disease of hematopoietic cells. Leukemia cells proliferate and accumulate in the bone marrow, lymph nodes and other hematopoietic systems due to their characteristics such as uncontrolled proliferation, blocked differentiation, and apoptosis, and infiltrate other tissues and organs in the body. organs, causing the normal hematopoietic function to be inhibited, resulting in anemia, hepatosplenomegaly and other symptoms. [0003] According to the pathogenesis of leukemia, it is divided into acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CML). Leukemia, CLL). [0004] Acute myelogenous...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61P35/02A61K36/37
CPCA61K31/585A61K36/37A61P35/02
Inventor 谭余庆刘丽李慧杰
Owner INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com